News

Greenfern reaches agreement with Cannvalate to develop its cannabis medicine sales in Australia

Greenfern reaches agreement with Cannvalate to develop its cannabis medicine sales in Australia

Greenfern Industries has reached an agreement with Australian-based Cannvalate Pty which will assist Greenfern (GFI) to develop its cannabis medicine sales in Australia, which are marketed under the GFI Pharma brand.

GFI chairman Brent King said the transaction includes the issuance of shares in Taranaki-based Greenfern to a value of NZD $900,000. GFI and Cannvalate will now move to finalise an agreement, which is compliant with Australian and New Zealand law and NZX listing rules.

Cannvalate has agreed to continue to range of GFI Pharma-branded medications and, under the terms of the agreement, they will educate physicians with the intention of securing exposure to 6000 patients. The agreement also means that GFI will have access to anonymised patient data which will contribute to the company’s research and development initiatives so it can develop and refine specific medications based on real world patient experiences.

Read more
Trichomes explained

Trichomes explained

Today we’re talking about trichomes - those tiny little crystal-looking structures that cover the leaves and buds of cannabis. 

The word trichomes comes from the Greek word trichōma, meaning hair. Trichomes are fine outgrowths on plants, algae and lichens. On cannabis they tend to be shiny, sticky, carry intense aromas and kind of look like a blanket of frost at first glance.

Read more

Search